We have previously found that the class I HDAC inhibitor (HDACi), entinostat (also known as MS-275 or SNDX-275) specifically enhanced expression of miR-125a, miR-125b, and miR-205, which acted in concert to downregulate ErbB2 and ErbB3 in ErbB2-overexpressing breast cancer cells [23, 24]. The gene discussed is ERBB2; the disease is breast cancer.